20 March 2020 01:13
(NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts on protecting our employees, producing critically needed medications, and turning our scientific and operational expertise towards identifying additional ways we may be able to assist in the massive prevention, diagnosis and treatment efforts needed to counter the spread of COVID-19. For example, in the immediate term, Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility in the U.S. to meet the potential for increased demand resulting from potential effectiveness of the product in treating COVID-19. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus. We look forward to working with governments and health authorities globally to ensure patient access to this medicine as and where needed.
Mylan expects to be in a position to begin supplying product by mid-April, and with the active pharmaceutical ingredient that we currently have available, will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients. Mylan takes its responsibility seriously and is committed to continuing to work with governments, partners and others to identify areas of need where our global R&D, regulatory and manufacturing expertise and capacity can be of service. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. This press release includes statements that constitute "forward-looking statements," including with regard to the potential approval and/or use of hydroxychloroquine sulfate tablets in the treatment of COVID-19; that Mylan expects to be in a position to begin supplying product by the second week of April, and with the active pharmaceutical ingredient that we currently have available will be able to ramp up manufacturing to provide 50 million tablets to potentially treat a total of more than 1.5 million patients; that the potential use of this medicine for COVID-19 related treatment is pending additional FDA and other regulatory body guidance; and that Mylan is committed to continuing to work with governments, partners and others to identify areas of need where our global R&D, regulatory and manufacturing expertise and capacity can be of service. Factors that could cause or contribute to such differences include, but are not limited to the impact of public health outbreaks and pandemics, such as the COVID-19 pandemic; any changes in, interruptions to, or difficulties with Mylan's or its partners' ability to develop, manufacture, and commercialize products; the effect of any changes in Mylan's or its partners' customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan or its partners; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on Mylan's or its partners' business; any regulatory, legal, or other impediments to Mylan's or its partners' ability to bring products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; Mylan's and its partners' ability to protect intellectual property and preserve intellectual property rights; risks associated with international operations; other uncertainties and matters beyond the control of management; and the other risks detailed in Mylan's filings with the Securities and Exchange Commission.
Mr Swinney, who is also deputy first minister, said the "unprecedented" move was a sign of the "gravity" of the situation the country was facing. A Dundee City Council spokesman said: "We are making progress in dealing with this unprecedented situation and we are looking at how we best use our schools to support vulnerable children, pupils completing SQA coursework and assessments and children of key workers. "Since the announcement was made yesterday, we have moved to identify those vulnerable young people who would receive support while the schools are closed. "We are discussing the recent announcement with head teachers and trade unions and will be providing further details on Friday that will cover the arrangements for the last week of the school term. Exams in Scottish schools this year have been cancelled as a result of the coronavirus outbreak, education secretary John Swinney announced.
All schools acorss the UK will close their doors from the end of Friday - apart from to children of key workers and the most vulnerable. Mr Williamson said schools will only re-open when it becomes clear that "is not going to have and impact in terms of spread of the pandemic". And he explained plans to cancel exams for around 5 million young people but still grade them so they can "have the best opportunities in terms of progressing their education, or going into work or on to college". He told Sky News' All Out Politics that vulnerable children - such as those at risk of abuse or who have a social worker - "will still be able to go to school". The government and the exams regulator Ofqal will also be discussing the "best, most accurate and fairest way" of grading students. "These days in schools there's a lot of data around, there's quite a lot of progress data, in some subjects there is assessment, there'll be mock exams in some cases," he said.